Jurjan Aman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in hospitalized patients with different severities of COVID‐19, and to assess the impact of critical illness and the potential drug–drug interaction with IL‐6R inhibitors on imatinib exposure. Imatinib, N‐desmethyl imatinib, and AAG were quantified from collected plasma samples. The PK data was further combined with previous data from COVID‐19 patients and chronic myelogenous leukemia/gastrointestinal stromal tumor (CML/GIST) patients who received imatinib. A population PK analysis was conducted using a standard sequential approach. Unbound fraction in COVID‐19 patients admitted to the intensive care unit (ICU) and treated with IL‐6R inhibitors was significantly elevated compared to CML/GIST patients (4.66% vs. 3.54% [1.08%–8.51%]; p < 0.001), despite twofold increased AAG levels. Our findings on total and unbound concentration show that cotreatment with IL‐6R inhibitor can lead to changes in metabolism and protein binding, suggesting similar implications for other highly protein bound drugs. Consequently, total concentrations may not accurately reflect unbound target site concentrations.
Year:
2025
This study is unique in that it phenotypes pulmonary edema in COVID-19 ARDS using various clinical parameters and biomarkers. First, there is a noteworthy tipping point in the amount of pulmonary edema at which ventilatory and clinical parameters deteriorate. Second, chest CT gives a good approximation of the amount of pulmonary edema. Finally, pulmonary vascular permeability is strongly reflected by inflammatory plasma proteins.
Year:
2025
Year:
2025
Background The sodium glucose cotransporter 2 (SGLT2) inhibitor may improve mitochondrial biogenesis and attenuate pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). We investigated the impact of empagliflozin in PAH. Methods Lung sections and primary cell cultures isolated from microvascular endothelial cells (MVECs) were collected from control subjects and PAH patients. MVECs were treated with empagliflozin and mitochondrial biogenesis, cell metabolism, oxidative stress and cell proliferation were evaluated. Subsequently, PAH was induced in male and female rats (n=12 respectively) with SU5416 injection (25 mg/kg s.c.) followed by 3 weeks of hypoxia (10% O 2 ), the experimental PAH model known to mimic human PAH pathophysiology. Four weeks after SU5416 injection, rats were treated by empagliflozin (300 mg/kg chow, n=12) or placebo (n=12) for 4 weeks and hemodynamic, protein and histological analyses were performed. In addition, we conducted a phase IIa proof of concept trial, EMPHOWER, to assess the feasibility of 12 weeks of empagliflozin treatment in PAH patients. Results Immunofluorescent staining of human lung tissue showed expression of SGLT2 in the intima of small pulmonary arteries from PAH patients, not controls. In comparison to control MVECs, PAH MVECs showed increased protein expression of SGLT2, along with decreased expression of the peroxisome proliferator-activated receptor gamma coactivator-1α. Furthermore, empagliflozin enhanced expression of mitochondrial encoded genes and mitochondrial respiration, suggesting increased mitochondrial biogenesis. Moreover, empagliflozin significantly attenuated oxidative stress and proliferation of PAH MVECs. In SuHx rats, chronic treatment with empagliflozin significantly reduced pulmonary vascular resistance and thickening of the intima of small pulmonary arteries. Finally, 8 patients diagnosed with idiopathic and heritable PAH were enrolled in the phase IIa EMPHOWER trial. There was no discontinuation of empagliflozin during the study period and there were no treatment associated serious adverse events. There were no changes in biomarkers, WHO functional class, six-minute walk distance, or EMPHASIS score. However, RV ejection fraction and RV global longitudinal strain slightly worsened after empagliflozin treatment (from 45 ± 10% to 38 ± 12%, P=0.036, and from −15.2 ± 4.2% to −13.2 ± 3.96%, P=0.002, respectively). Conclusion SGLT2 expression is increased in the PAH endothelium. Treatment with empagliflozin improves mitochondrial biogenesis and attenuates proliferation of PAH MVECs. Empagliflozin attenuates pulmonary vascular remodeling in experimental PAH. While twelve weeks of empagliflozin treatment seemed feasible in patients with idiopathic or hereditary PAH, we observed signs of RV deterioration. Clinical perspective What is new? This is the first study to demonstrate the role of sodium glucose cotransporter 2 (SGLT2) in the endothelial cell proliferation of pulmonary arterial hypertension (PAH). SGLT2 was expressed and increased in microvascular endothelial cells (MVECs) from the lung of PAH patients accompanied by suppression of peroxisome proliferator-activated receptor gamma coactivator-1α. Empagliflozin improved mitochondrial biogenesis and respiration in PAH MVECs. Empagliflozin reversed pulmonary angioproliferation and attenuated pulmonary vascular resistance in experimental PAH rats. The EMPHOWER PoC study showed the feasibility of 12 weeks of empagliflozin treatment in PAH, however, right ventricular function assessed by cardiac magnetic resonance imaging worsened. What are the clinical implications SGLT2 inhibition may improve mitochondrial respiration and reverse pulmonary vascular remodeling in PAH. The effect of empagliflozin on right ventricular function requires further caution and investigation.
Year:
2025
Rationale Approximately 80% of patients with non-familial pulmonary arterial hypertension (PAH) lack identifiable pathogenic genetic variants. While most genetic studies of PAH have focused on predicted loss-of-function variants, recent approaches have identified ultra-rare missense variants associated with the disease. FOXF1 encodes a highly conserved transcription factor, essential for angiogenesis and vasculogenesis in human and mouse lungs. Objectives We identified a rare FOXF1 missense coding variant in two unrelated probands with PAH. FOXF1 is an evolutionarily conserved transcription factor required for lung vascular development and vascular integrity. Our aims were to determine the frequency of FOXF1 variants in larger PAH cohorts compared to the general population, study FOXF1 expression in explanted lung tissue from PAH patients versus control (failed-donor) lungs, and define potential downstream targets linked to PAH development. Methods Three independent, international, multicenter cohorts were analyzed to evaluate the frequency of FOXF1 rare variants. Various composite prediction models assessed the deleteriousness of individual variants. Bulk RNA sequencing datasets from human explanted lung tissues were compared to failed-donor controls to determine FOXF1 expression. Bioinformatic tools identified putative FOXF1 binding targets, which were orthogonally validated using mouse ChIP-seq datasets. Measurements and Main Results Seven novel or ultra-rare missense coding variants were identified across three patient cohorts in different regions of the FOXF1 gene, including the DNA binding domain. FOXF1 expression was dysregulated in PAH lungs, correlating with disease severity. Histological analysis showed heterogeneous FOXF1 expression, with the lowest levels in phenotypically abnormal endothelial cells within complex vascular lesions in PAH samples. A hybrid bioinformatic approach identified FOXF1 downstream targets potentially involved in PAH pathogenesis, including BMPR2 . Conclusions Large genomic and transcriptomic datasets suggest that decreased FOXF1 expression or predicted dysfunction is associated with PAH.
Year:
2024
Increasing evidence indicates that inflammation promotes thrombosis via a VWF (von Willebrand factor)-mediated mechanism. VWF plays an essential role in maintaining the balance between blood coagulation and bleeding, and inflammation can lead to aberrant regulation. VWF is regulated on a transcriptional and (post-)translational level, and its secretion into the circulation captures platelets upon endothelial activation. The significant progress that has been made in understanding transcriptional and translational regulation of VWF is described in this review. First, we describe how VWF is regulated at the transcriptional and post-translational level with a specific focus on the influence of inflammatory and immune responses. Next, we describe how changes in regulation are linked with various cardiovascular diseases. Recent insights from clinical diseases provide evidence for direct molecular links between inflammation and thrombosis, including atherosclerosis, chronic thromboembolic pulmonary hypertension, and COVID-19. Finally, we will briefly describe clinical implications for antithrombotic treatment.
Year:
2022
Collaborators (20)
Marion Delcroix
University Hospitals Leuven
Frances Handoko-de Man
Amsterdam UMC Locatie VUmc
j.w.r. twisk
Amsterdam UMC Locatie VUmc
Vinicio de Jesus Perez
Stanford University
William Zacharias
Associate Professor
Cincinnati Children's Hospital Medical Center
Michael Pauciulo
Assistant Professor
Cincinnati Children's Hospital Medical Center
Eleonora Swart
Head of Department
Amsterdam UMC Locatie AMC
Asger Andersen
VIP, Associate Professor
Aarhus University
Imke H. Bartelink
-
Christopher Rhodes
Lecturer in Digital Media Production
University College London
Arjan C Houweling
Clinical Geneticist, Associate Professor
Amsterdam University Medical Centers
Stefan Gräf
Research Professor of Computational Genomics & Genomic Medicine
University of Cambridge
Keimei Yoshida
Kyushu University
Wendy Chung
Kennedy Family Professor
Boston Children's Hospital
Harm Jan Bogaard
Professor of Medicine
VU medisch centrum
Jose Gomez-Arroyo
Assistant Professor
University of Cincinnati
Lieuwe D. J. Bos
University of Amsterdam
Francis McCormack
Division Chief
University of Cincinnati
Morten Kvistholm Jensen
Aarhus University
Vladimir Kalinichenko
Professor and Director
University of Arizona College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.